—
C+
C+ The full Closelooknet — membership. Open the C+ overview

Axsome Therapeutics Inc (AXSM) — chart, structure and Closelooknet read

Pick a ticker to load its detail page.

Signals for this name

Every Closelooknet reading that exists for AXSM, from the same nightly bakes the boards use. Research diary readings, not advice.

Weather around the name 3 macro readings: Money Temperature, Factor regime, Sovereign pressure

The weather around this name

Macro readings that apply by membership — the regime, the factor tape, the sector cell, the funding backdrop.

  • Money Temperature Composite 61/100 · S&P 500 fund at 75, bullish alignedEight instruments scored on position, momentum, volume, volatility and fragility — the regime every name trades inside. Temperature lab → 2026-10-06
  • Factor regime Momentum leading — risk appetite buildingMomentum against low volatility (SPMO / SPLV): above its 50-day trend, 98th percentile of the window, +5.7% over 20 sessions. Factor regime → 2026-10-06
  • Sovereign pressure Index 0.74 · up 0.17 over 21 sessionsG7 long-end yields, 10s30s and the slope — the funding weather for every balance sheet on this site. Sovereign pressure → 2026-10-06
How it trades on rate days beta 0.14 to TLT · on the worst bond days it moved with the market

How it trades on rate days

How AXSM has moved when long-dated Treasury yields rise — measured against TLT, the 20+ year Treasury fund.

  • Beta to long bonds, 1 year 0.14 — shows only a loose link to bond moves for every 1% move in TLT (20+ year Treasuries), Axsome Therapeutics Inc moved 0.14% on average · correlation 0.03 · higher than 16% of US names
  • Beta, last 3 months 0.87 more rate-sensitive lately than over the year
  • On the 10 worst bond days −0.94% on average against −0.74% for the S&P 500 the 10 sessions of the past year in which TLT fell most, i.e. long yields rose most
  • Latest of those days +1.33% TLT −1.29% that day 2026-09-24

Daily total returns from the adjusted price series; a TLT down day is a day long yields rose. Beta = the average move of the name for a 1% move in TLT. Past sensitivity, not a forecast. An investment diary, not a recommendation.

Who it is priced against Biotechnology · US · 8 names with week and year-to-date

Peer group

Biotechnology · US

This name carries no Closelooknet score, so its cohort ranks on trend state — distance to the 50- and 200-day averages — never on a score it does not have.

Compared against AXSM on the nightly bakes; the Peers tab ranks the cohort on the Closelooknet scores where it exists.

Company snapshot — Axsome Therapeutics Inc

AXSM in five paragraphs: what it makes and sells, where it sits in the Closelooknet stack, who it is priced against, why we track it, what we watch. Research diary, not advice.

What it does
Axsome Therapeutics is a biopharmaceutical company that develops treatments for central nervous system disorders, based in New York. Its marketed products are Auvelity for major depressive disorder, Sunosi for excessive daytime sleepiness in narcolepsy or sleep apnoea, and Symbravo for acute migraine. Its pipeline includes AXS-05 for Alzheimer's agitation, AXS-12 and AXS-14 for conditions such as narcolepsy and fibromyalgia, and a further trial of solriamfetol across several disorders.
Where it sits in the stack
Axsome carries no seat in our Rubin or Halo indices, so it sits outside the diary's build-out stacks; it belongs to the Healthcare sector of the US universe, where it is tracked as a commercial-stage CNS drugmaker rather than as a supplier to any technology layer.
Who it is priced against
Closelooknet's peer group places it with other scored Healthcare names from the US market, chosen for sharing its sector and country: argenx, Medpace, BeiGene, Globus Medical, Regeneron, Veeva Systems, Vertex Pharmaceuticals and Corcept Therapeutics.
Why Closelooknet tracks it
Axsome carries a Closelooknet score, with momentum the strongest of its modules and valuation the weakest; it holds no index seat and has not yet appeared in the diary's editions or quotes.
What the diary watches
The diary watches whether the pipeline readouts, particularly AXS-05 in Alzheimer's agitation, add to the commercial portfolio or remain trial-stage.

Axsome Therapeutics Inc (AXSM) trades on US exchanges.

Written from the company’s public profile and Closelooknet’s own readings, 2026-09-17. Descriptive, refreshed with the registry; corrections welcome via the imprint. closelook.net is an investment research diary — market structure, index membership and scores are our own readings, not investment advice. Related: index compare · sector dispersion · scanner.

The Street on this name 2 analyst actions on the wire · latest: price target by Deutsche Bank, 2026-09-29

The Street on this name

Analyst actions and the latest print for AXSM from the Closelooknet wires — third-party opinions on the record, not our readings.

  • Price target Deutsche Bank — target 267 from 280 Target cut to $267 from $280 (+41.5% to spot) 2026-09-29
  • Price target Morgan Stanley — target 247 from 251 Target cut to $247 from $251 (+24.4% to spot) 2026-09-25

2 actions on the analyst wire since 2026-08-13: 2 target changes. Analyst wire → · Earnings wire →

FAQ · from the current data · as of 2026-10-07

Quick answers

What is Axsome Therapeutics Inc (AXSM)?

Axsome Therapeutics Inc trades as AXSM on the US exchange (US) in the Closelooknet research universe, as of the registry build of 2026-10-07.

Is AXSM in a Closelooknet index?

Not currently — Axsome Therapeutics Inc is tracked in the Closelooknet research universe but is not a constituent of a Closelooknet functional index as of 2026-10-07.

Where does AXSM trade against its moving averages?

Mixed moving-average stack: Trades -15.7% vs the 50-day and -12.9% vs the 200-day average, 33% below the 52-week high and +48.6% off the 52-week low. Computed from daily closes. As of 2026-10-06 — a technical state from the nightly Closelooknet bake, not advice. The Technical tab carries the full row.

How does Axsome Therapeutics Inc compare with its peers?

Against its peer group (Biotechnology · US), Axsome Therapeutics Inc (AXSM) sits 33.0% below its 52-week high, 15.7% below its 50-day average; BeiGene, Ltd. (ONC) is 5.8% below, Regeneron Pharmaceuticals Inc (REGN) is 15.5% below, Caris Life Sciences, Inc. Common Stock (CAI) is 18.4% below. Put any of them next to AXSM in the chart grid (2×1 or 2×2) and the page lays the companies side by side: performance, trend, valuation, margins and our money-flow reading.

How does Axsome Therapeutics Inc trade when bond yields rise?

Over the past year Axsome Therapeutics Inc had a beta of 0.14 to TLT, the long-dated Treasury fund — it shows only a loose link to bond moves, higher than 16% of US names. On the 10 sessions in which long bonds fell most it moved −0.94% on average, against −0.74% for the S&P 500. The "How it trades on rate days" block on this page carries the lines.

What does Axsome Therapeutics Inc do?

Axsome Therapeutics is a biopharmaceutical company that develops treatments for central nervous system disorders, based in New York. Its marketed products are Auvelity for major depressive disorder, Sunosi for excessive daytime sleepiness in narcolepsy or sleep apnoea, and Symbravo for acute migraine. Its pipeline includes AXS-05 for Alzheimer's agitation, AXS-12 and AXS-14 for conditions such as narcolepsy and fibromyalgia, and a further trial of solriamfetol across several disorders. Closelooknet's peer group places it with other scored Healthcare names from the US market, chosen for sharing its sector and country: argenx, Medpace, BeiGene, Globus Medical, Regeneron, Veeva Systems, Vertex Pharmaceuticals and Corcept Therapeutics.

Where does Axsome Therapeutics Inc sit in the AI build-out?

Axsome carries no seat in our Rubin or Halo indices, so it sits outside the diary's build-out stacks; it belongs to the Healthcare sector of the US universe, where it is tracked as a commercial-stage CNS drugmaker rather than as a supplier to any technology layer. Axsome carries a Closelooknet score, with momentum the strongest of its modules and valuation the weakest; it holds no index seat and has not yet appeared in the diary's editions or quotes.

What has Wall Street done on Axsome Therapeutics Inc recently?

The most recent analyst action on Axsome Therapeutics Inc on the Closelooknet wire is a price target by Deutsche Bank on 2026-09-29 (target 267 from 280). 2 actions on the analyst wire since 2026-08-13: 2 target changes. Analyst actions are third-party opinions recorded by the wire, not Closelooknet readings. The “The Street on this name” block on this page lists the moves; the full feeds are the analyst wire and the earnings wire.

What does this page show?

A live price chart with SMA overlays and drawing tools for AXSM, performance metrics, index-membership context and the Closelooknet structure read — an investment research diary view, not investment advice.

Related in the Closelooknet universe

then Biotechnology. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.